var data={"title":"Sevelamer: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sevelamer: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6948?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sevelamer-drug-information\" class=\"drug drug_general\">see &quot;Sevelamer: Drug information&quot;</a> and <a href=\"topic.htm?path=sevelamer-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sevelamer: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220777\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Renagel;</li>\n      <li>Renvela</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220778\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Renagel;</li>\n      <li>Renvela</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062073\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Phosphate Binder</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062067\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sevelamer-drug-information\" class=\"drug drug_general\">see &quot;Sevelamer: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Phosphate binding capacity: Sevelamer HCl 400 mg binds ~32 mg of phosphate; 800 mg binds ~64 mg of phosphate (KDOQI 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperphosphatemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Sevelamer</i>\n      <i> carbonate (Renvela): </i>Children &ge;6 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients not taking a phosphate binder: Initial:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">BSA &ge;0.75 to &lt;1.2 m<sup>2</sup>: 800 mg 3 times daily with meals; titrate as needed by 400 mg per dose at 2 week intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">BSA &ge;1.2 m<sup>2</sup>: 1,600 mg 3 times daily with meals; titrate as needed by 800 mg per dose at 2 week intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosage adjustment when switching from calcium acetate to sevelamer carbonate:</i> 667 mg of calcium acetate is equivalent to ~800 mg sevelamer; conversion based on dose per meal:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Calcium acetate 667 mg: Convert to 800 mg sevelamer carbonate</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Calcium acetate 1,334 mg: Convert to 1,600 mg sevelamer carbonate</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Calcium acetate 2,001 mg: Convert to 2,400 mg sevelamer carbonate</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Sevelamer hydrochloride (Renagel):</i> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;10 months and Children &lt;2 years: Oral: Mean final dose: 140 &plusmn; 86 mg/kg/day (5.38 &plusmn; 3.24 <b>g</b>/day) was reported in a small trial (n=18, age range: 10 months to 18 years) to achieve the targeted serum phosphorus level. Initial dosing was based upon prior phosphate binder dose and serum phosphorus concentrations (Pieper 2006). In a case report of a 19-month old, an initial dose of 100 mg/kg/day divided every 8 hours with titration up to 130 mg/kg/day was reported to effectively lower serum phosphorus levels (Storms 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;2 years and Adolescents: Oral: Initial dose: 400 or 800 mg 3 times daily administered with meals; titrate at monthly intervals in 1,200 mg/day increments (ie, 400 mg at each meal) to target phosphorus level; final mean range: 140 to 163 mg/kg/day (5.38 to 6.7 <b>g</b>/day); dosing based on experience in 46 patients; prior or final comparative calcium salt phosphate-binder dose: 4 &plusmn; 3 <b>g</b>/day (Gulati 2010; Mahdavi 2003; Pieper 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosage adjustment when switching from calcium acetate to sevelamer hydrochloride:</i> 667 mg of calcium acetate is equivalent to ~800 mg sevelamer; conversion based on dose per meal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperphosphatemia, pretreatment of oral and enteral nutrition:</b> Limited data available: Oral: 800 mg (tablets or powder) added to up to 400 mL of breast milk or 100 mL of infant formula, tube feeding, and cow's milk; after sitting for 10 minutes, decant liquid from the precipitate at the bottom; reported experience has shown a decrease in phosphate of &gt;85% in breast milk, 42% in cow's milk, 48% in tube feeding, and 68% in infant formula (KDOQI 2009; Raaijmakers 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note: </b>The dosing of sevelamer carbonate and sevelamer hydrochloride are similar; when switching from one product to another, the same dose (on a mg per mg basis) should be utilized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Control of serum phosphorus:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients not taking a phosphate binder: Initial: 800 to 1,600 mg 3 times daily with meals; the initial dose may be based on the serum phosphorus:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum phosphorus &gt;5.5 mg/dL to &lt;7.5 mg/dL: 800 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum phosphorus &ge;7.5 mg/dL to &lt;9 mg/dL: 1,200 to 1,600 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum phosphorus &ge;9 mg/dL: 1,600 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose adjustment based on serum phosphorous concentration [goal range: 3.5 to 5.5 mg/dL; maximum dose studied was equivalent to 13 <b>g</b>/day (sevelamer hydrochloride) or 14 <b>g</b>/day (sevelamer carbonate)]:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum phosphorus &gt;5.5 mg/dL: Increase by 400 to 800 mg per meal at 2-week intervals</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum phosphorus 3.5 to 5.5 mg/dL: Maintain current dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum phosphorus &lt;3.5 mg/dL: Decrease by 400 to 800 mg per meal</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment when switching between phosphate-binder products:</i> 667 mg of calcium acetate is equivalent to ~800 mg sevelamer (carbonate or hydrochloride); conversion based on dose per meal:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Calcium acetate 667 mg: Convert to 800 mg Renagel/Renvela</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Calcium acetate 1,334 mg: Convert to 1,600 mg as Renagel/Renvela (800 mg tablets x 2) <b>or</b> 1,200 mg as Renagel (400 mg tablets x 3)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Calcium acetate 2,001 mg: Convert to 2,400 mg as Renagel/Renvela (800 mg tablets x 3) <b>or</b> 2,000 mg as Renagel (400 mg tablets x 5)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220760\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral, as carbonate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renvela: 0.8 g (1 ea, 90 ea); 2.4 g (1 ea, 90 ea) [citrus flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.8 g (1 ea, 90 ea); 2.4 g (1 ea, 90 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as carbonate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renvela: 800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renagel: 400 mg [DSC], 800 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220745\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062076\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer with meals. Consider separating administration of oral medications from sevelamer when reduced bioavailability would significantly affect the concomitant medication's safety or efficacy (eg, cyclosporine, tacrolimus, levothyroxine); duration of separation varies based on absorption characteristics and whether it is an immediate release or extended release product; monitor clinical response and/or blood concentrations of concomitant medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Swallow tablets whole; do not break, chew, or crush; contents will expand with water.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for oral suspension (sevelamer carbonate): Administer reconstituted oral suspension immediately or within 30 minutes; oral suspension may need to be resuspended immediately before drinking. Alternatively, the powder contents of the packet may be pre-mixed with a small amount of food or beverage and consumed immediately (or within 30 minutes) as part of a meal. Do not heat or add to heated food or liquid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220773\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062075\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Reduction of serum phosphorus in patients with chronic kidney disease on hemodialysis (Renvela: FDA approved in patients &ge;6 years and adults; Renagel: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220802\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renagel may be confused with Reglan, Regonol, Renvela </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renvela may be confused with Reglan, Regonol, Renagel</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sevelamer may be confused with Savella</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Renagel [US, Canada, and multiple international markets] may be confused with Remegel brand name for aluminium hydroxide and magnesium carbonate [Netherlands] and for calcium carbonate [Hungary, Great Britain and Ireland] and with Remegel Wind Relief brand name for calcium carbonate and simethicone [Great Britain]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220800\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypercalcemia, metabolic acidosis (more common in children [Pieper 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, nausea, peritonitis (peritoneal dialysis), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Fecal impaction, hypersensitivity reaction, intestinal obstruction (rare), intestinal perforation (rare)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220765\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to sevelamer or any component of the formulation; bowel obstruction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypophosphatemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220749\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal effects: Bowel obstruction and perforation have been reported. Dysphagia and esophageal tablet retention have also been reported with the tablet formulation; consider change to suspension formulation in patients with a history of swallowing disorders</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal disease: Use with caution in patients with gastrointestinal disorders including dysphagia, swallowing disorders, severe gastrointestinal motility disorders (including severe constipation), or major gastrointestinal surgery. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vitamins: May cause reductions in vitamin D, E, K, or folic acid absorption. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tablets: Should not be taken apart or chewed; broken or crushed tablets will rapidly expand in water/saliva and may be a choking hazard.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25956001\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In a trial conducted in pediatric patients (n=18; age range: 10 months to 18 years), an increase in metabolic acidosis was noted in the sevelamer treatment group (incidence: 34.4%) (Pieper 2006); in another pediatric trial (n=17, age range: 2 to 18 years), no untoward effects were reported (Mahdavi 2003). Patients should be closely monitored.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300038\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220754\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12975&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Calcitriol (Systemic): Sevelamer may decrease the serum concentration of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholic Acid: Sevelamer may decrease the absorption of Cholic Acid.  Management: Administer cholic acid at least 1 hour before or 4 to 6 hours after administration of any bile acid-binding products, such as sevelamer, to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Sevelamer may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Sevelamer may decrease the serum concentration of Levothyroxine.  Management: Consider separating administration of sevelamer and levothyroxine by at least several hours whenever possible in order to decrease the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Sevelamer may decrease the serum concentration of Mycophenolate.  Management: Administer mycophenolate at least 2 hours prior to sevelamer administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Sevelamer may decrease the absorption of Quinolones.  Management: Administer oral quinolones at least 2 hours before or 6 hours after sevelamer.<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Sevelamer may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13851538\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">May cause reductions in vitamin D, E, K, or folic acid absorption. Management: Must be administered with meals. Consider vitamin supplementation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220756\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220768\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Sevelamer is not absorbed systemically; however, it may cause a reduction in the absorption of fat soluble vitamins and folic acid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062072\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">General recommendations: Serum chemistries (eg, bicarbonate, chloride, magnesium), creatinine, BUN, and albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">KDIGO 2017 guidelines: <b>Note:</b> Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral and bone disorders</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">CKD</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Calcium</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Phosphorous</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Alkaline Phosphatase</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">PTH</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">G2 to G3b</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 6 to 12 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 6 to 12 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Based on clinical condition</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Based on baseline and progression of disease</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">G4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 3 to 6 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 3 to 6 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 12 months (more often in presence of elevated PTH)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 6 to 12 months</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">G5 and G5d</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 1 to 3 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 1 to 3 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 12 months (more often in presence of elevated PTH)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Every 3 to 6 months</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22464289\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corrected total serum calcium (KDIGO 2017): CKD stages 3a to 5D:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: Maintain in age-appropriate normal ranges</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Avoid hypercalcemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus (KDIGO 2017):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD G3a to G5D: Lower elevated phosphorus levels toward the normal range</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220748\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sevelamer (a polymeric compound) binds phosphate within the intestinal lumen, limiting absorption and decreasing serum phosphate concentrations without altering calcium, aluminum, or bicarbonate concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220764\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Reduction in serum phosphorus has been demonstrated after 1-2 weeks (Burke 1997; Chertow 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Not systemically absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22464290\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic Kidney Disease (CKD):</b> Children &ge;2 years, Adolescents, and Adults: CKD is defined as GFR &lt;60 mL/minute/1.73 m<sup>2</sup> or kidney damage for &gt;3 months; GFR category, albuminuria category, and cause of kidney damage are used in conjunction to assign a stage (KDIGO 2012; KDIGO 2017):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR categories:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">G1: Normal or increased GFR; GFR &ge;90 mL/minute/1.73 m<sup>2 </sup>WITH kidney damage</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">G2: Mild decrease in GFR; GFR 60 to 89 mL/minute/1.73 m<sup>2</sup> WITH kidney damage</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">G3a: Mild to moderate decrease in GFR; GFR 45 to 59 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">G3b: Moderate to severe decrease in GFR; GFR 30 to 44 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CKD G4: Severe decrease in GFR; GFR 15 to 29 mL/minute/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CKD G5: Kidney failure; GFR &lt;15 mL/minute/1.73 m<sup>2</sup> or dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Albuminuria categories:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">A1: Normal or mildly increased</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">A2: Moderately increased</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">A3: Severely increased</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220767\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Renvela Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8 g (1): $20.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.4 g (1): $20.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Sevelamer Carbonate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8 g (1): $11.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.4 g (1): $11.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Renagel Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (180): $1,524.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Renvela Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (270): $1,828.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sevelamer Carbonate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (270): $1,021.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038827\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Inophos (BD);</li>\n      <li>Invela (KR);</li>\n      <li>Postiline (AR);</li>\n      <li>Renagel (AE, AT, AU, BB, BR, CR, CY, DO, ES, FI, GR, GT, HN, HR, IE, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, NI, PA, PE, PL, PT, QA, RO, SA, SI, SK, SV, TR, TW, UY);</li>\n      <li>Renosev (BD);</li>\n      <li>Renvela (AE, AT, BB, BE, CH, CL, CN, CR, CY, CZ, DE, DK, DO, EE, ES, FR, GB, GT, HK, HN, HR, ID, IE, IL, IS, KR, KW, LB, LT, LU, LV, MT, MY, NI, NL, NO, PA, PH, PL, PT, RO, SA, SE, SG, SI, SK, SV, TH, TR);</li>\n      <li>Sevel (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. <i>Nephrol Dial Transplant</i>. 1997;12(8):1640-1644.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-pediatric-drug-information/abstract-text/9269642/pubmed\" target=\"_blank\" id=\"9269642\">9269642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. <i>Am J Kidney Dis</i>. 1997;29(1):66-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-pediatric-drug-information/abstract-text/9002531/pubmed\" target=\"_blank\" id=\"9002531\">9002531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gulati A, Sridhar V, Bose T, Hari P, Bagga A. Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4. <i>Int Urol Nephrol</i>. 2010;42(4):1055-1062.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-pediatric-drug-information/abstract-text/20020207/pubmed\" target=\"_blank\" id=\"20020207\">20020207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). <i>Kidney Int Suppl</i>. 2017;7:1-59.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Inter</i>. 2013;3:1-150.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahdavi H, Kuizon BD, Gales B, et al, &ldquo;Sevelamer Hydrochloride: An Effective Phosphate Binder in Dialyzed Children,&rdquo; <i>Pediatr Nephrol</i>, 2003, 18(12):1260-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-pediatric-drug-information/abstract-text/14586677/pubmed\" target=\"_blank\" id=\"14586677\">14586677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. <i>Am J Kidney Dis</i>. 2005;46:S1-S122.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation. KDOQI clinical practice guideline for nutrition in children with CKD: 2008 update. <i>Am J Kidney Dis</i>. 2009;53:S1-S124.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-pediatric-drug-information/abstract-text/19231749/pubmed\" target=\"_blank\" id=\"19231749\">19231749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pieper AK, Haffner D, Hoppe B, et al, &quot;A Randomized Crossover Trial Comparing Sevelamer With Calcium Acetate in Children With CKD,&quot; <i>Am J Kidney Dis</i>, 2006, 47(4):625-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-pediatric-drug-information/abstract-text/16564940/pubmed\" target=\"_blank\" id=\"16564940\">16564940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raaijmakers R, Houkes LM, Schr&ouml;der CH, et al. Pre-treatment of dairy and breast milk with sevelamer hydrochloride and sevelamer carbonate to reduce phosphate. <i>Perit Dial Int</i>. 2013;33(5):565-572.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-pediatric-drug-information/abstract-text/23636435/pubmed\" target=\"_blank\" id=\"23636435\">23636435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Renagel (sevelamer hydrochloride) [prescribing information]. Cambridge, MA: Genzyme Corp; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Renvela (sevelamer carbonate) [prescribing information]. Cambridge, MA: Genzyme Corp; May 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Renvela (sevelamer carbonate) [prescribing information]. Cambridge, MA: Genzyme Corp; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Storms LE, Chicella MF, Dice JE. Sevelamer therapy for pediatric end-stage renal disease. <i>Pharmacotherapy</i>. 2006;26(3):410-413.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sevelamer-pediatric-drug-information/abstract-text/16503722/pubmed\" target=\"_blank\" id=\"16503722\">16503722</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12975 Version 127.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F220777\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F220778\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062073\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062067\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F220760\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F220745\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062076\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F220773\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062075\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F220802\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F220800\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F220765\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F220749\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25956001\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300038\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F220754\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F13851538\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F220756\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F220768\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062072\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F22464289\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F220748\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F220764\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F22464290\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F220767\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038827\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12975|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sevelamer-drug-information\" class=\"drug drug_general\">Sevelamer: Drug information</a></li><li><a href=\"topic.htm?path=sevelamer-patient-drug-information\" class=\"drug drug_patient\">Sevelamer: Patient drug information</a></li></ul></div></div>","javascript":null}